NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $3.00 -0.07 (-2.28%) As of 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sana Biotechnology Stock (NASDAQ:SANA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sana Biotechnology alerts:Sign Up Key Stats Today's Range$2.97▼$3.1650-Day Range$2.68▼$3.8252-Week Range$1.98▼$6.55Volume2.69 million shsAverage Volume3.03 million shsMarket Capitalization$834.87 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingModerate Buy Company Overview Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function. The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials. Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic. Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.AI Generated. May Contain Errors. Read More Sana Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreSANA MarketRank™: Sana Biotechnology scored higher than 47% of companies evaluated by MarketBeat, and ranked 549th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSana Biotechnology has a consensus price target of $9.50, representing about 215.6% upside from its current price of $3.01.Amount of Analyst CoverageSana Biotechnology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sana Biotechnology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($0.62) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 7.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.40% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 13.16, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 0.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest17 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat Follows10 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SANA Stock News HeadlinesAnalyzing Sana Biotechnology (NASDAQ:SANA) and Stoke Therapeutics (NASDAQ:STOK)May 19, 2026 | americanbankingnews.comSana Biotechnology Raises $69 Million Through Equity OfferingMay 15, 2026 | tipranks.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 26 at 1:00 AM | Brownstone Research (Ad)Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market FacilityMay 15, 2026 | marketwatch.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityMay 15, 2026 | globenewswire.comSana Biotechnology (SANA) Receives a Buy from WedbushMay 14, 2026 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)May 13, 2026 | theglobeandmail.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell ...May 13, 2026 | markets.businessinsider.comSee More Headlines SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $4.07 at the beginning of the year. Since then, SANA shares have decreased by 26.0% and is now trading at $3.01. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $552 million in an IPO on Wednesday, February 3rd 2021. The company issued 23,500,000 shares at $23.00-$24.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's top institutional investors include Bank of America Corp DE (1.06%), Renaissance Technologies LLC (0.52%), Bank of New York Mellon Corp (0.16%) and Swiss National Bank (0.13%). Insiders that own company stock include Robert Nelsen, Fmr Llc, Richard Mulligan and Ventures Fund V Gener Flagship. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sana Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings5/11/2026Today5/26/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 12 days, SANA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SANA CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees380Year Founded2018Price Target and Rating Average Price Target for Sana Biotechnology$9.50 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+214.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$244.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.01% Return on Assets-40.68% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book7.02Miscellaneous Outstanding Shares278,290,000Free Float207,606,000Market Cap$840.44 million OptionableOptionable Beta2.17 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:SANA) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYou cannot escape this realityThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredThe digital asset institutions are buying before headlines hitJPMorgan is processing $2 billion a day through new digital rails. BlackRock's tokenized fund crossed $2.8 bil...Awesomely, LLC | SponsoredNearly Half of Americans Are ExposedDr. David Eifrig, former Goldman Sachs insider and CEO of one of the largest financial research firms in the w...Stansberry Research | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
